Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: A double-blind randomized controlled trial

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Na, Lixin ^a   Zhang, Qiao ^a   Jiang, Shuo ^a   Du, Shanshan ^a   Zhang, Wei ^a   Li, Ying ^a   Sun, Changhao ^a   Niu, Yucun ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; ACETOACETIC ACID DERIVATIVE; CARNITINE; FATTY ACID; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN LIPASE; MANGIFERIN; PLACEBO; XANTHONE DERIVATIVE;

BLOOD; CONTROLLED STUDY; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

3-HYDROXYBUTYRIC ACID; ACETOACETATES; BLOOD GLUCOSE; CARNITINE; CHOLESTEROL, HDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPIDS; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; OVERWEIGHT; PLACEBOS; XANTHONES;

EID: 84930207594     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10344     Document Type: Article

References (43)

1. Lucchi, T. & Vergani, C. [Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature]. G Ital Cardiol (Rome). 15, 149-60 (2014).
2. Yin, K. & Tang, C. Inflammation, lipid metabolism dysfunction, and hypertension: active research fields in atherosclerosis-related cardiovascular disease in China. Sci China Life Sci. 54, 976-9 (2011).
3. Nordestgaard, B.G. & Varbo, A. Triglycerides and cardiovascular disease. Lancet. 384, 626-35 (2014).
4. Austin, M.A. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol. 83, 13F-16F (1999).
5. Matsumoto, S., et al. The role of hypertriglyceridemia in the development of atherosclerosis and endothelial dysfunction. Nutrients. 6, 1236-50 (2014).
6. Pirro, M., et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis. 160, 377-84 (2002).
7. Frohnert, B.I., et al. Relation between serum free fatty acids and adiposity, insulin resistance, and cardiovascular risk factors from adolescence to adulthood. Diabetes. 62, 3163-9 (2013).
8. Brewer, H.B., Jr. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. Clin. Cardiol. 26, III19-24 (2003).
9. Preiss, D. & Sattar, N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin. Endocrinol. (Oxf). 70, 815-28 (2009).
10. Wlotzke, U., Hohenleutner, U., Abd-El-Raheem, T.A., Baumler, W. & Landthaler, M. Side-effects and complications of flashlamppumped pulsed dye laser therapy of port-wine stains. A prospective study. Br. J. Dermatol. 134, 475-80 (1996).
11. Kiortsis, D.N., Nikas, S., Hatzidimou, K., Tsianos, E. & Elisaf, M.S. Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. Fundam Clin. Pharmacol. 17, 491-4 (2003).
12. Muscari, A., Puddu, G.M. & Puddu, P. Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology. 97, 115-21 (2002).
13. Matkowski, A., Kus, P., Goralska, E. & Wozniak, D. Mangiferin-a bioactive xanthonoid, not only from mango and not just antioxidant. Mini Rev. Med. Chem. 13, 439-55 (2013).
14. Gong, X., et al. Anti-inflammatory effects of mangiferin on sepsis-induced lung injury in mice via up-regulation of heme oxygenase-1. J. Nutr. Biochem. 24, 1173-81 (2013).
15. Prabhu, S., Jainu, M., Sabitha, K.E. & Devi, C.S. Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats. J. Ethnopharmacol. 107, 126-33 (2006).
16. Sellamuthu, P.S., Arulselvan, P., Fakurazi, S. & Kandasamy, M. Beneficial effects of mangiferin isolated from Salacia chinensis on biochemical and hematological parameters in rats with streptozotocin-induced diabetes. Pak J. Pharm. Sci. 27, 161-7 (2014).
17. Rodriguez, J., et al. Effects of a natural extract from Mangifera indica L, and its active compound, mangiferin, on energy state and lipid peroxidation of red blood cells. Biochim. Biophys. Acta. 1760, 1333-42 (2006).
18. Miura, T., et al. The suppressive effect of mangiferin with exercise on blood lipids in type 2 diabetes. Biol. Pharm. Bull. 24, 1091-2 (2001).
19. Guo, F., et al. Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol. Nutr. Food Res. 55, 1809-18 (2011).
20. Niu, Y., et al. Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. PLoS One. 7, e30782 (2012).
21. Hou, S., et al. Pharmacokinetic study of mangiferin in human plasma after oral administration. Food Chem. 132, 289-94 (2012).
22. Lam, T.K. & Leung, D.T. More on simplified calculation of body-surface area. N Engl. J. Med. 318, 1130 (1988).
23. Rodriguez, M., et al. Plasma fatty acids and [13C]linoleic acid metabolism in preterm infants fed a formula with medium-chain triglycerides. J. Lipid Res. 44, 41-8 (2003).
24. Bjorntorp, P. Liver triglycerides and metabolism. Int. J. Obes. Relat. Metab. Disord. 19, 839-40 (1995).
25. Volek, J.S., et al. Effects of a high-fat diet on postabsorptive and postprandial testosterone responses to a fat-rich meal. Metabolism. 50, 1351-5 (2001).
26. Ringseis, R. & Eder, K. Regulation of genes involved in lipid metabolism by dietary oxidized fat. Mol. Nutr. Food Res. 55, 109-21 (2011).
27. Franssen, R., Monajemi, H., Stroes, E.S. & Kastelein, J.J. Obesity and dyslipidemia. Med. Clin. North. Am. 95, 893-902 (2011).
28. Brautbar, A., et al. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 53, 556-60 (2012).
29. Lim, J., et al. Dual mode action of mangiferin in mouse liver under high fat diet. PLoS One. 9, e90137 (2014).
30. Apontes, P., et al. Mangiferin stimulates carbohydrate oxidation and protects against metabolic disorders induced by high-fat diets. Diabetes. 63, 3626-36 (2014).
31. Nielsen, S. & Karpe, F. Determinants of VLDL-triglycerides production. Curr. Opin. Lipidol. 23, 321-6 (2012).
32. Ebbert, J.O. & Jensen, M.D. Fat depots, free fatty acids, and dyslipidemia. Nutrients. 5, 498-508 (2013).
33. Votruba, S.B. & Jensen, M.D. Regional fat deposition as a factor in FFA metabolism. Annu. Rev. Nutr. 27, 149-63 (2007).
34. Teusink, B., et al. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes. 52, 614-20 (2003).
35. Stephens, F.B. & Galloway, S.D. Carnitine and fat oxidation. Nestle Nutr. Inst. Workshop Ser. 76, 13-23 (2013).
36. Wutzke, K.D. & Lorenz, H. The effect of l-carnitine on fat oxidation, protein turnover, and body composition in slightly overweight subjects. Metabolism. 53, 1002-6 (2004).
37. Ramos-Roman, M.A., Sweetman, L., Valdez, M.J. & Parks, E.J. Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity. Metabolism. 61, 202-12 (2012).
38. Fukao, T., et al. Ketone body metabolism and its defects. J. Inherit. Metab. Dis. 37, 541-51 (2014).
39. Plourde, M., Tremblay-Mercier, J., Fortier, M., Pifferi, F. & Cunnane, S.C. Eicosapentaenoic acid decreases postprandial betahydroxybutyrate and free fatty acid responses in healthy young and elderly. Nutrition. 25, 289-94 (2009).
40. Keller, U., Gerber, P.P. & Stauffacher, W. Fatty acid-independent inhibition of hepatic ketone body production by insulin in humans. Am. J. Physiol. 254, E694-9 (1988).
41. Trumbo, P., Schlicker, S., Yates, A.A. & Poos, M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 102, 1621-30 (2002).
42. Liu, L., et al. Free fatty acid metabolic profile and biomarkers of isolated post-challenge diabetes and type 2 diabetes mellitus based on GC-MS and multivariate statistical analysis. J. Chromatogr B Analyt Technol. Biomed Life Sci. 878, 2817-25 (2010).
43. Moro, E., et al. Hypertriglyceridemia is associated with increased insulin resistance in subjects with normal glucose tolerance: evaluation in a large cohort of subjects assessed with the 1999 World Health Organization criteria for the classification of diabetes. Metabolism. 52, 616-9 (2003).